Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
vlag Redhill Biopharma 12/12 1,205 USD
+0,43% 		+0,43%
vlag Regeneron Pharmaceuticals, Inc. 15/12 752,620 USD
+1,53% 		+1,53%
vlag Repare Therapeutics Inc 15/12 2,200 USD
+2,80% 		+2,80%
vlag Rhythm Pharmaceuticals Inc. 12/12 113,560 USD
-3,45% 		-3,45%
vlag Rigel Pharmaceuticals 15/12 42,480 USD
+4,17% 		+4,17%
vlag Rocket Pharmaceuticals Inc 15/12 3,410 USD
+0,59% 		+0,59%

Nieuws over “Fabricage van farmaceutische preparaten”

00:00 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 · Persbericht

00:00 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 · Persbericht

15/12 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

15/12 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

15/12 · RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells · Persbericht

15/12 · Johnson & Johnson krijgt boete van 40 miljoen dollar in zaak rond kankerverwekkend talkpoeder · Business AM

Key takeaways Twee Californische vrouwen krijgen een schadevergoeding van in totaal 40 miljoen dollar (34 miljoen euro) van Johnson & Johnson. De jury achtte het bedrijf verantwoordelijk voor de diagnose van hun eierstokkanker....

15/12 · Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis · Persbericht

15/12 · Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis · Persbericht

13/12 · U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* · Persbericht

12/12 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12/12 · Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 · Persbericht

12/12 · Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer · Persbericht

12/12 · Abbott increases quarterly dividend for 54th consecutive year · Persbericht

12/12 · AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs · Persbericht

12/12 · Levi & Korsinsky Notifies Shareholders of Perrigo Company plc(PRGO) of a Class Action Lawsuit and an Upcoming Deadline · Persbericht

11/12 · Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference · Persbericht

11/12 · Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress · Persbericht

11/12 · AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease · Persbericht

11/12 · Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial · Persbericht

11/12 · Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases · Persbericht

11/12 · Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. · Persbericht

Mijn selecties